Background: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). Methods: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone. Results: Sixty-three out of 71 patients who received RT for LGG were deemed eligible for evaluation of psPD. The median follow-up was 5 years (range 1‒10 y). PsPD was seen in 13 patients (20.6%). PsPD occurred after a median of 12 months with a range of 3-78 months. The median duration of psPD was 6 months, with a range of 2-26 months and always occurred within the RT high dose fields of at least 45 Gy. The area of the enhancement at the time of psPD was significantly smaller compared with the area of enhancement during "true" progression (median size 54mm2 [range 12-340mm2] vs 270mm2 [range 30-3420mm2], respectively; P = .009). Conclusions: PsPD occurs frequently in LGG patients receiving RT. This supports the policy to postpone a new line of treatment until progression is evident, especially when patients have small contrast enhancing lesions within the RT field.
Background: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). Methods: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone. Results: Sixty-three out of 71 patients who received RT for LGG were deemed eligible for evaluation of psPD. The median follow-up was 5 years (range 1‒10 y). PsPD was seen in 13 patients (20.6%). PsPD occurred after a median of 12 months with a range of 3-78 months. The median duration of psPD was 6 months, with a range of 2-26 months and always occurred within the RT high dose fields of at least 45 Gy. The area of the enhancement at the time of psPD was significantly smaller compared with the area of enhancement during "true" progression (median size 54mm2 [range 12-340mm2] vs 270mm2 [range 30-3420mm2], respectively; P = .009). Conclusions: PsPD occurs frequently in LGG patients receiving RT. This supports the policy to postpone a new line of treatment until progression is evident, especially when patients have small contrast enhancing lesions within the RT field.
Authors: Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan Journal: J Neurooncol Date: 2006-08-31 Impact factor: 4.130
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch Journal: Neurosurg Focus Date: 2015-01 Impact factor: 4.047
Authors: Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent Journal: Lancet Neurol Date: 2010-08-10 Impact factor: 44.182
Authors: M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs Journal: Lancet Oncol Date: 2011-04-05 Impact factor: 41.316
Authors: Robert P Naftel; Ian F Pollack; Giulio Zuccoli; Melvin Deutsch; Regina I Jakacki Journal: Pediatr Blood Cancer Date: 2014-09-11 Impact factor: 3.167
Authors: Ingo K Mellinghoff; Susan M Chang; Kurt A Jaeckle; Martin van den Bent Journal: Hematol Oncol Clin North Am Date: 2021-10-25 Impact factor: 2.861
Authors: Haroon Ahmad; David Martin; Sohil H Patel; Joseph Donahue; Beatriz Lopes; Benjamin Purow; David Schiff; Camilo E Fadul Journal: J Neurooncol Date: 2019-09-23 Impact factor: 4.130
Authors: Ethan B Ludmir; Anita Mahajan; Arnold C Paulino; Jeremy Y Jones; Leena M Ketonen; Jack M Su; David R Grosshans; Mary Frances McAleer; Susan L McGovern; Yasmin A Lassen-Ramshad; Adekunle M Adesina; Robert C Dauser; Jeffrey S Weinberg; Murali M Chintagumpala Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: M Back; D Jayamanne; D Brazier; A Newey; D Bailey; G Schembri; E Hsiao; M Khasraw; M Wong; M Kastelan; C Brown; H Wheeler Journal: Strahlenther Onkol Date: 2019-04-26 Impact factor: 4.033
Authors: Christina M Flies; Karlijn H van Leuken; Marlies Ten Voorde; Joost J C Verhoeff; Filip Y F De Vos; Tatjana Seute; Pierre A Robe; Theodoor D Witkamp; Jeroen Hendrikse; Jan Willem Dankbaar; Tom J Snijders Journal: Neurology Date: 2022-04-18 Impact factor: 11.800
Authors: Todd C Hollon; Balaji Pandian; Esteban Urias; Akshay V Save; Arjun R Adapa; Sudharsan Srinivasan; Neil K Jairath; Zia Farooq; Tamara Marie; Wajd N Al-Holou; Karen Eddy; Jason A Heth; Siri Sahib S Khalsa; Kyle Conway; Oren Sagher; Jeffrey N Bruce; Peter Canoll; Christian W Freudiger; Sandra Camelo-Piragua; Honglak Lee; Daniel A Orringer Journal: Neuro Oncol Date: 2021-01-30 Impact factor: 12.300